Alongside the release of abstracts related to the American Society of Hematology meeting next month in San Diego, and as part of the firm’s third-quarter update, Beam Therapeutics Inc. disclosed that one patient died in the phase I/II trial testing BEAM-101 in sickle cell disease (SCD).
Randy Osborne is a staff writer for BioWorld Today, a publication focused on the biotechnology industry. With a talent for storytelling and a knack for creating new things, Randy's articles cover a wide range of topics within the biotech field, including company developments, clinical trials, and industry trends.